NCT05256797View on ClinicalTrials.gov

Prediction of the COBRRA AF Anticoagulant Trial in Healthcare Claims Data

CompletedOBSERVATIONAL
Enrollment

353,980

Participants

Timeline

Start Date

May 3, 2021

Primary Completion Date

June 15, 2022

Study Completion Date

June 15, 2022

Conditions
Atrial Fibrillation
Interventions
DRUG

Rivaroxaban

Any rivaroxaban dispensing claim is used as the reference group

DRUG

Apixaban

Any apixaban dispensing claim is used as the exposure group

Trial Locations (1)

02120

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER